|
|
|
Welcome: March 2017
Welcome to our first ever Milner Newsletter. We’ll be using our newsletter as a primary vehicle to help you to deliver your therapeutic and business goals. Our mission is to create a therapeutic ecosystem in Cambridge with global outreach. Our ambition is to connect as many of our affiliate companies and academics as possible.
|
 |
For companies: We intend this newsletter to
inform you about other companies and also to give you space to share your news with the academic and industrial community. We want to do our best to help you be more effective in your mission.
|
|
For academics: We will be raising awareness of companies working in your area who are looking for collaborations and partnerships in Cambridge. We’ll also be giving opportunities to talk to companies for advice on how to translate your research.
|
|
Future:
We will be including news and information from our affiliate companies, job opportunities and local events. If you have anything to share please drop us a line. We are keen to widen our distribution list so please forward to anyone with an interest in therapeutic research.
|
|
Milner News
In the last month we have welcomed five new companies to our affiliate partnership scheme: Genedata, Metrion Bioscience, Biomax, Censo and Exonate. Links to all our affiliate partners are on our website Read more »
We are delighted to announce that Elysium Health has joined the Milner Therapeutics Consortium to invest in collaborative research with Cambridge academic scientists Read more »
|
|
| Affiliated Company News |
|
Metrion Biosciences announces two new partnerships to strengthen their Ion Channel Drug Discovery Service Read more » |
|
Repositive launch autism-related data collection, and celebrate 1000 users
Read more » |
|
Protein Microcrystals may repair damaged cartilage at an earlier stage in osteoarthritis: Cell Guidance Systems announces new collaboration
Read more » |
|
Strem partners with Apeiron to spread the word about their creation of new catalysts and applications
Read more » |
|
ActiveMotif publish on their alternative ChIP-Seq normalisation approach in PLOSOne
Read more » |
|
Diagenode releases complete product solution for RNA sequencing using Capture and Amplification by Tailing and Switching (CATS)
Read more » |
|
Exonate awarded £4.9m from Wellcome Trust to continue development of treatment for wet age-related macular degeneration
Read more »
|
Affiliated Company Spotlight
|
|
Our vision is a world where epigenetics helps to tackle the most pressing issues of our time and improves health and wellness for everyone.
|
Jason Mellad, CEO
|
Here at Cambridge Epigenetix we believe great things happen when people work together. The biggest leaps in human understanding come from collaboration: when the right specialisms, interests and ambitions combine, the benefits are exponential.
Our new biomarker discovery and development service puts our expertise at your disposal, so we can enrich your understanding, and vice versa.
We have brought together world-leading experts in epigenetics, genomics and the development of next generation sequencing technology. The company is headquartered in Cambridge, UK, and is financed by leading venture capital companies including GV (Google Ventures), Sequoia Capital, Syncona, New Science Ventures, and University of Cambridge. Contact Jason Mellad at Jason@cegx.co.uk
Exonate’s pipeline of novel small molecule inhibitors is designed to address areas of significant unmet medical need..
|
Catherine Beech, CEO
|
Exonate is a biopharmaceutical company, based in Nottingham and Cambridge, focused on the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need. Alternative mRNA splicing is modulated in disease states resulting in pathological blood vessel formation (angiogenesis), which is a key driver of disease progression in ophthalmic conditions and cancer.
Exonate’s founders have identified and generated a novel class of drugs, “SPHINXes,” that modulate alternative mRNA splicing. We have developed a pipeline of molecules that promise therapeutics for anti-angiogenic therapies in ophthalmology, oncology, analgesia, diabetes, neurodegeneration and renal disease. The Company has grown significantly in the last year as it welcomes investment and input from an increasing Global market. Contact Louise Shave at Louise.shave@exonate.com
|
|
| Local Events |
|
Promega Discover Glo European Tour, April 2017 Attend a symposium in London (5th), Babraham (6th) or Cambridge (7th) and discover how new luminescent technologies are improving reporter assays and allowing researchers to study protein interactions and target engagement in real time in live cells.
All events are free and include lunch and refreshments, but places are limited so please register now to book your place Further info » |
|
Cambridge Ion Channel Forum, Cambridge 21st April 2017 Metrion and Medimmune will co-host the fourth Cambridge Ion Channel Forum in the Sir Aaron Klug building on Granta Park. The keynote speaker will be Professor John Wood from University College London, with his presentation entitled: Nav1.7 as an analgesic drug target. Tony Rush from Metrion will be presenting Mind the Gap: Translational Neuroscience at Metrion Further info » |
|
Drug Discovery Workshop, 10th May 2017 Cambridge Academy of Therapeutic Sciences (CATS) and the Milner Therapeutics Institute will be jointly hosting a training seminar on data needs in drug discovery, presented by Dr Olaf Ritzeler, External Innovation Lead Europe at Sanofi-Aventis.
The seminar is open to academics from across the University of Cambridge and also welcomes participants from biotech companies Further info » |
|
Repositive's First User Party, 6th April 2017 To celebrate reaching 1000 global users, we want to organise our first ever user party. This party is completely free with a healthy tab behind the bar and sharing platters for all. The main purpose for this party is to simply celebrate and say thank you to you, our users, for joining the Repositive community. However, whilst all under one roof, you can meet your fellow users and there is plenty of opportunity to network and form any collaborations.
Registration is free and places will be offered on a first-come-first-served basis Further info » |
|
Judge Business School Strategy Programme, various dates
The portfolio of strategy programmes provides business managers and directors with a versatile, strategic toolkit to give coherence and direction to the actions and decisions of the organisation.
Further info » |
|
| Jobs |
|
Opportunities at Exonate Exonate are currently looking to recruit a senior scientist of pharmacology. Read more » |
|
Opportunities at Repositive There are currently job opportunities for a lead frontend engineer, lead backend engineer, and business development manager. Read more » |
|
|
